TX-PANDA-BIOTECH
3.4.2024 15:01:28 CEST | Business Wire | Press release
Panda Biotech™ announced today that commercial operations have officially begun at the Panda Hemp Gin, their landmark industrial hemp processing facility in Wichita Falls, Texas. The 500,000-square-foot building situated on 97 acres is the first of its kind and the largest in the Western Hemisphere, with the capacity to process 10 metric tons of industrial hemp into textile-grade fiber, hurd, short-fiber/hurd mix, and nutrient-rich micronized hurd per hour. It is a zero-waste process, utilizing every part of the industrial hemp stalk, and operates solely on 100 percent renewable energy, making it a paragon of sustainability in the industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240403426324/en/
Panda Hemp Gin is a 500,000-square-foot building situated on 97 acres with the capacity to process 10 metric tons of industrial hemp into textile-grade fiber, hurd, short-fiber/hurd mix, and nutrient-rich micronized hurd per hour. (Photo: Business Wire)
The Panda Hemp Gin is fully operational, and production will continue to ramp up in the coming months. In February, the complex commissioning process of Panda's 600-yard-long processing line and three miles of overhead pneumatic duct lines, including each piece of equipment for decortication, refining, blending, mechanical cottonization, hurd bagging and storage, and baling, was successfully completed.
"Panda Biotech's state-of-the-art industrial hemp processing facility is a monumental achievement and a game-changer for both agriculture and industry,” said Dixie Carter, president of Panda Biotech. “As research and development in this area continue to advance, industrial hemp fiber and cellulose will help transform numerous industries with sustainable goals and challenges. Panda’s industrial hemp will play a pivotal role in satisfying significant global market demand for renewable processes and products.”
Industrial hemp is considered one of the most versatile raw materials available with an unmatched variety of potential uses. The Panda Hemp Gin will focus on providing five main product lines from hemp, including mechanically cottonized fiber, decorticated fiber, hurd (cellulose), short-fiber/hurd mix, and nutrient-rich micronized hemp dust. The innumerous applications for each product vary broadly from consumer and industrial textiles, non-wovens, paper products, bioplastics, biofuel, animal bedding, fiberglass substitute, construction materials such as hempcrete, mulch, insulation, and more.
With a commitment to traceability and processing only U.S.-grown hemp straw, as well as providing an astounding pay-to-grow program, Panda’s partnership with the American farming community is at the heart of the operation. Industrial hemp provides a multitude of benefits for producers, as it is scientifically proven to minimize CO2 emissions, absorbing more per acre than any forest or commercial crop. Additionally, hemp requires significantly less water than most major crops, provides outstanding soil remediation, and requires minimal fertilizers, pesticides, and herbicides. Panda is actively contracting with producers for its pay-to-grow program for this harvest and with farmers who may have straw or fiber from previous harvests or the 2024 growing season. Interested producers can reach out to Panda through the website at pandabiotech.com.
"The massive scale of the campus, allowing more than 22,000 pounds of baled hemp straw for processing per hour, is what makes this industrial hemp processing facility unique,” said Scott Evans, chief operating officer of Panda Biotech. “Our straw is sourced directly from our farming partners in Texas and surrounding states, and, through our decortication process, it is transformed into packaged products, ready for retail or downstream manufacturing applications, within minutes. Panda's processing equipment and infrastructure is truly best-in-class."
For more information, please visit www.pandabiotech.com and follow us at @pandabiotech on Facebook, Instagram, X, and LinkedIn.
ABOUT PANDA BIOTECH
Based in Dallas, Texas, privately-held Panda Biotech, LLC is a first-mover in the emerging U.S. industrial hemp fiber and hurd industry that is 100 percent American-owned, grown, and processed. Panda Biotech’s executive leadership has extensive experience developing, financing, constructing, and operating large-scale infrastructure facilities in clean energy. They have developed 22 projects representing approximately $12 billion in invested capital. Panda Biotech’s first project, the Panda Hemp Gin™, is in partnership with Aka-Ag, LLC, a wholly-owned subsidiary of the Southern Ute Indian Tribe Growth Fund. The facility is located in Wichita Falls, Texas. It is the largest industrial hemp processing facility of its kind in the Western Hemisphere.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403426324/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
